Secukinumab-induced Raynaud’s phenomenon: first report in the literature

Secukinumab is an IL-17A antagonist that has proven efficacy in the treatment of patients with ankylosing spondylitis (AS) and psoriatic arthritis. Side effects of the drug include infections, skin rashes, and allergic reactions. Raynaud’s phenomenon (RP), a vasospastic syndrome and an important fea...

Descripción completa

Detalles Bibliográficos
Autor principal: Kobak, Senol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036488/
https://www.ncbi.nlm.nih.gov/pubmed/32128108
http://dx.doi.org/10.1177/2042098620905976
_version_ 1783500228212555776
author Kobak, Senol
author_facet Kobak, Senol
author_sort Kobak, Senol
collection PubMed
description Secukinumab is an IL-17A antagonist that has proven efficacy in the treatment of patients with ankylosing spondylitis (AS) and psoriatic arthritis. Side effects of the drug include infections, skin rashes, and allergic reactions. Raynaud’s phenomenon (RP), a vasospastic syndrome and an important feature of different connective tissue diseases, is not an expected finding in AS patients. This article reports the development of secukinumab-related RP in a 35-year-old female patient with AS. Treatment with secukinumab was continued and RP was treated with low-dose aspirin and a calcium-channel blocker.
format Online
Article
Text
id pubmed-7036488
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-70364882020-03-03 Secukinumab-induced Raynaud’s phenomenon: first report in the literature Kobak, Senol Ther Adv Drug Saf Case Report Secukinumab is an IL-17A antagonist that has proven efficacy in the treatment of patients with ankylosing spondylitis (AS) and psoriatic arthritis. Side effects of the drug include infections, skin rashes, and allergic reactions. Raynaud’s phenomenon (RP), a vasospastic syndrome and an important feature of different connective tissue diseases, is not an expected finding in AS patients. This article reports the development of secukinumab-related RP in a 35-year-old female patient with AS. Treatment with secukinumab was continued and RP was treated with low-dose aspirin and a calcium-channel blocker. SAGE Publications 2020-02-22 /pmc/articles/PMC7036488/ /pubmed/32128108 http://dx.doi.org/10.1177/2042098620905976 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Kobak, Senol
Secukinumab-induced Raynaud’s phenomenon: first report in the literature
title Secukinumab-induced Raynaud’s phenomenon: first report in the literature
title_full Secukinumab-induced Raynaud’s phenomenon: first report in the literature
title_fullStr Secukinumab-induced Raynaud’s phenomenon: first report in the literature
title_full_unstemmed Secukinumab-induced Raynaud’s phenomenon: first report in the literature
title_short Secukinumab-induced Raynaud’s phenomenon: first report in the literature
title_sort secukinumab-induced raynaud’s phenomenon: first report in the literature
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036488/
https://www.ncbi.nlm.nih.gov/pubmed/32128108
http://dx.doi.org/10.1177/2042098620905976
work_keys_str_mv AT kobaksenol secukinumabinducedraynaudsphenomenonfirstreportintheliterature

Ejemplares similares